Page 4 - reflections_dyslipidaemia_newsletter5_2023
P. 4
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #6 2023
prevent recurrent events and to optimize cardiovascular risk. After an ACS event, LLT should be initiated as early as possible,
This consists of medical therapy, lifestyle changes, and cardiac preferably with a high-intensity statin, or a statin with the addition
rehabilitation, as well as consideration of psychosocial factors. of ezetimibe, if the patient is already on maximally tolerated
Dyslipidaemia
statin dose or has LDL-C levels which indicate that it is unlikely
Focusing on the guidelines’ stance on lipid-lowering therapy to reach the target with statin therapy alone. In all cases, lipid
(LLT), the task force suggests that dyslipidaemia should be levels should be re-evaluated 4–6 weeks after each treatment
managed according to the current dyslipidaemia guidelines, with or dose adjustment to determine whether treatment goals have
a combination of lifestyle and pharmacological interventions. been achieved and to check for any safety issues.
a Consider LDL-C <1.0 mmol/L if recurrent event.
TABLE OF CONTENTS
